Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening.

"Competing interests DAMH, RDMS and CJLMM are minority shareholders of Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc; Self-screen B.V. develops, manufactures and licences high-risk HPV and methylation marker assays for cervical cancer screening and holds patents on these tests; JB had financial support from the European Commission (RISCC, grant number 847845); CJLMM is part-time CEO of Self-screen B.V., and has a very small number of shares of MDXHealth and previously QIAGEN, has received speakers fees from GSK, QIAGEN and SPMSD/Merck, and served occasionally on the scientific advisory boards of these companies; LV, MCGB, NP, RMFE, WJGM, RLMB, ACM, WGQ and FJvK declare no competing interests."

"Funding This project was funded by the Dutch Cancer Society (grant number KWF 11337)."